Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beam Therapeutics’ stock is on the rise due to Jefferies initiating coverage with a Buy rating, driven by the promising potential of BEAM-302 for treating Alpha-1 Antitrypsin Deficiency. Despite JPMorgan slightly lowering its price target, they maintain an Overweight rating, indicating continued confidence. Additionally, Cathie Wood’s ARK Investment bolstered investor sentiment by purchasing 491,000 shares, further boosting the stock’s appeal.
More about Beam Therapeutics
YTD Price Performance: 9.31%
Average Trading Volume: 2,554,195
Technical Sentiment Signal: Buy
Current Market Cap: $2.54B
For further insights into BEAM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.